EHMT2 and neoplasm: Although a correlation between baseline levels of G9a or H3K9me2 and tumour responses was not observed, our in vitro and in vivo studies showed that anti-tumour efficacy due to pharmacological inhibition of methyltransferase activity of G9a and DNMTs was associated with global reductions in H3K9me2 and 5mC levels.